Click Here for Session Questions: Q&A and Polling

SESSION I: ACUTE LYMPHOBLASTIC LEUKEMIA 

Session Chair: Session Chairs: Josep-Maria Ribera and Partow Kebriaei

Welcome and Opening Remarks | Guillermo Garcia-Manero, MD | President, Society of Hematologic Oncology

Pharmacodynamics in Pediatric ALL | Rachel E Rau, MD | Seattle Children’s Hospital, Seattle, Washington, USA

Success of Modified AYA Therapy in Mexico | Roberta Demichelis, MD | Salvador Zubirán National Institute of Medical Sciences, Mexico City, Mexico

Incorporating Immunotherapy into Upfront ALL Therapy | Mark R Litzow, MD | Mayo Clinic Rochester, Rochester, Minnesota, USA

CAR-T Cells for T Cell | Peihua Lu, MD | Lu Daopei Hospital, Beijing, China

Transplant in ALL, Who, and When | Partow Kebriaei, MD | MD Anderson Cancer Center, Houston, Texas, USA

Debate: Ph + ALL Can Be Treated With - Chemotherapy Free Regimens Without Transplant | Elias Jabbour, MD | MD Anderson Cancer Center, Houston, Texas, USA

Debate: Ph + ALL Is Best Treated With - Chemotherapy and Transplant | Josep-Maria Ribera, MD, PhD | Institut Català d’Oncologia Badalona, Barcelona, Spain

Oral Abstract | ALL-173: Evolution of Tisagenlecleucel Use for the Treatment of Pediatric and Young Adult Relapsed/Refractory (R/R) B-Cell Acute Lymphoblastic Leukemia (B-ALL): Center for International Blood & Marrow Transplant Research (CIBMTR) Registry Results | Rayne H Rouce, MD | Texas Children's Cancer Center, Houston, Texas, USA

Oral Abstract | ALL-808: Very Promising Results of the Dose Dense (D-D) Mini-Hyper-CVD-Inotuzumab-Blinatumomab Phase 2 Trial in Patients with Relapsed- Refractory Acute Lymphoblastic Leukemia | Elias Jabbour, MD | MD Anderson Cancer Center, Houston, Texas, USA